These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9421873)

  • 1. Investigating underlying risk as a source of heterogeneity in meta-analysis.
    Thompson SG; Smith TC; Sharp SJ
    Stat Med; 1997 Dec; 16(23):2741-58. PubMed ID: 9421873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline risk as predictor of treatment benefit: three clinical meta-re-analyses.
    Arends LR; Hoes AW; Lubsen J; Grobbee DE; Stijnen T
    Stat Med; 2000 Dec; 19(24):3497-518. PubMed ID: 11122510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysing the relationship between treatment effect and underlying risk in meta-analysis: comparison and development of approaches.
    Sharp SJ; Thompson SG
    Stat Med; 2000 Dec; 19(23):3251-74. PubMed ID: 11113958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment.
    Pagliaro L; D'Amico G; Sörensen TI; Lebrec D; Burroughs AK; Morabito A; Tiné F; Politi F; Traina M
    Ann Intern Med; 1992 Jul; 117(1):59-70. PubMed ID: 1350716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relation between treatment benefit and underlying risk in meta-analysis.
    Sharp SJ; Thompson SG; Altman DG
    BMJ; 1996 Sep; 313(7059):735-8. PubMed ID: 8819447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis of prophylactic endoscopic sclerotherapy for esophageal varices.
    Fardy JM; Laupacis A
    Am J Gastroenterol; 1994 Nov; 89(11):1938-48. PubMed ID: 7942715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Explaining heterogeneity in meta-analysis: a comparison of methods.
    Thompson SG; Sharp SJ
    Stat Med; 1999 Oct; 18(20):2693-708. PubMed ID: 10521860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Borrowing strength from external trials in a meta-analysis.
    Higgins JP; Whitehead A
    Stat Med; 1996 Dec; 15(24):2733-49. PubMed ID: 8981683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The implications of publication bias for meta-analysis' other parameter.
    Jackson D
    Stat Med; 2006 Sep; 25(17):2911-21. PubMed ID: 16345059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the treatment effect on recurrent bleeding and death in patients with cirrhosis and esophageal varices: multistage competing-risks model compared to conventional methods. The Copenhagen Esophageal Varices Sclerotherapy Project.
    Thomsen BL; Sørensen TI
    J Hepatol; 1998 Jan; 28(1):107-14. PubMed ID: 9537847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic sclerotherapy of high-risk esophageal varices: results of a multicentric prospective controlled trial.
    Piai G; Cipolletta L; Claar M; Marone G; Bianco MA; Forte G; Iodice G; Mattera D; Minieri M; Rocco P
    Hepatology; 1988; 8(6):1495-500. PubMed ID: 3056821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic sclerotherapy of large esophageal varices.
    Santangelo WC; Dueno MI; Estes BL; Krejs GJ
    N Engl J Med; 1988 Mar; 318(13):814-8. PubMed ID: 3281001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic sclerotherapy in children with esophageal varices: long-term results of a controlled prospective randomized trial.
    Gonçalves ME; Cardoso SR; Maksoud JG
    J Pediatr Surg; 2000 Mar; 35(3):401-5. PubMed ID: 10726678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of prophylactic sclerotherapy for prevention of a first variceal hemorrhage.
    Van Ruiswyk J; Byrd JC
    Gastroenterology; 1992 Feb; 102(2):587-97. PubMed ID: 1531046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoscopic sclerotherapy compared with no specific treatment for the primary prevention of bleeding from esophageal varices. A randomized controlled multicentre trial [ISRCTN03215899].
    van Buuren HR; Rasch MC; Batenburg PL; Bolwerk CJ; Nicolai JJ; van der Werf SD; Scherpenisse J; Arends LR; van Hattum J; Rauws EA; Schalm SW
    BMC Gastroenterol; 2003 Aug; 3():22. PubMed ID: 12919638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales.
    Warn DE; Thompson SG; Spiegelhalter DJ
    Stat Med; 2002 Jun; 21(11):1601-23. PubMed ID: 12111922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of endoscopic variceal sclerotherapy in the long-term management of variceal bleeding: a meta-analysis.
    Infante-Rivard C; Esnaola S; Villeneuve JP
    Gastroenterology; 1989 Apr; 96(4):1087-92. PubMed ID: 2784398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic sclerotherapy for esophageal varices: long-term results of a prospective study.
    Koch H; Binmoeller KF; Grimm H; Soehendra N; Henning H; Oehler G
    Endoscopy; 1994 Nov; 26(9):729-33. PubMed ID: 7712966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerotherapy versus vasoactive drugs: are all meta-analyses the same?
    Triantos C; Samonakis D; Patch D; Burroughs A; Goulis J
    Gastroenterology; 2004 Jul; 127(1):358-9; author reply 359-60. PubMed ID: 15236217
    [No Abstract]   [Full Text] [Related]  

  • 20. Prophylactic endoscopic sclerotherapy in patients with liver cirrhosis, portal hypertension, and esophageal varices.
    Paquet KJ; Kuhn R
    Hepatogastroenterology; 1997; 44(15):625-36. PubMed ID: 9222663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.